Madrigal Pharmaceuticals Stock (NASDAQ:MDGL)
Previous Close
$295.13
52W Range
$200.08 - $377.46
50D Avg
$325.28
200D Avg
$291.82
Market Cap
$6.64B
Avg Vol (3M)
$375.40K
Beta
-0.92
Div Yield
-
MDGL Company Profile
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
MDGL Performance
Peer Comparison
| Ticker | Company |
|---|---|
| TGTX | TG Therapeutics, Inc. |
| SRPT | Sarepta Therapeutics, Inc. |
| ETNB | 89bio, Inc. |
| VKTX | Viking Therapeutics, Inc. |
| IOVA | Iovance Biotherapeutics, Inc. |
| PTCT | PTC Therapeutics, Inc. |
| KRYS | Krystal Biotech, Inc. |
| MREO | Mereo BioPharma Group plc |
| HEPA | Hepion Pharmaceuticals, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| PLRX | Pliant Therapeutics, Inc. |